UTI, Inc.

As of June 30, 2026, UTI, Inc. carries a market capitalization of 80.08B, placing it among publicly traded companies globally. Its enterprise value stands at 158.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, UTI, Inc. has 19.58M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.96, and the price-to-book ratio stands at 1.11.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 158.92B versus a market cap of 80.08B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, UTI, Inc. maintains a current ratio of 0.29, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 115.33, indicating elevated leverage, while an interest coverage ratio of -3.65 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, UTI, Inc. posted a negative return on equity (ROE) of -30.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.15, reflecting losses generated across the asset base. The company generates approximately 155.71M in revenue per employee across its workforce of 128.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.18 indicates how many times UTI, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, UTI, Inc. recorded 2.90B in income tax expense. The company reported a pretax loss of -15.44B and -18.34B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, UTI, Inc.'s stock has declined approximately 92.81% over the past 52 weeks. The 50-day moving average sits at 2,336.30, while the 200-day moving average is 13,024.37.

Over the twelve months ended June 30, 2026, UTI, Inc. generated 20.01B in revenue and converted that into -18.34B in net income, yielding earnings per share of -901.51. EBITDA reached -39.75B, while operating income came in at -58.09B.

As of June 30, 2026, UTI, Inc. holds 4.41B in cash and equivalents against 83.22B in total debt, resulting in a net debt position of 75.90B. Total book value stands at 72.13B, with working capital of -65.17B providing operational flexibility.

UTI, Inc. produced -37.76B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -75.21B in capital expenditures, free cash flow totaled -112.97B - equivalent to -5,829.53 per share.

Over the twelve months ended June 30, 2026, UTI, Inc. posted a gross margin of -145.30, reflecting its pricing power and cost economics. The operating margin of -290.32 and net profit margin of -91.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -135.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -126.29, meaning UTI, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

UTI, Inc.'s most recent stock split took place on November 8, 2018 with a 1:3 split ratio.

As of June 30, 2026, UTI, Inc. has an Altman Z-Score of -1.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.